A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study)

被引:18
作者
Hazama, Shoichi [1 ]
Maeda, Hiromichi [2 ]
Iwamoto, Shigeyoshi [3 ]
Kim, Ho Min [4 ]
Takemoto, Hiroyoshi [5 ]
Kobayashi, Kenji [6 ]
Sakamoto, Junichi [7 ]
Nagata, Naoki [8 ]
Oba, Koji [9 ]
Mishima, Hideyuki [10 ]
机构
[1] Yamaguchi Univ, Grad Sch Med, Dept Gastroenterol Breast & Endocrine Surg, Ube, Yamaguchi, Japan
[2] Kochi Univ, Canc Treatment Ctr, Nankoku, Kochi, Japan
[3] Kansai Med Univ, Hirakata Hosp, Hirakata, Osaka, Japan
[4] Osaka Rosai Hosp, Div Surg, Sakai, Osaka, Japan
[5] Kinki Cent Hosp, Dept Surg, Itami, Hyogo, Japan
[6] Matsunami Gen Hosp, Dept Surg, Hashima, Japan
[7] Tokai Cent Hosp, Kakamigahara, Japan
[8] Kitakyushu Gen Hosp, Kitakyushu, Fukuoka, Japan
[9] Univ Tokyo, Grad Sch Med, Dept Biostat, Tokyo, Japan
[10] Aichi Med Univ, Ctr Canc, Nagakute, Aichi, Japan
关键词
Capecitabine; EGFR; Erbitax; Hand-foot symdrome; HFS; CAPECITABINE PLUS OXALIPLATIN; MRC COIN TRIAL; CLINICAL-TRIAL; MULTICENTER; CHEMOTHERAPY; COMBINATION; FLUOROPYRIMIDINE; BEVACIZUMAB; STANDARD; FOLFOX-6;
D O I
10.1016/j.clcc.2016.07.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this clinical trial we evaluated the safety and efficacy of cetuximab with capecitabine/oxaliplatin treatment among the 40 eligible patients with epidermal growth factor receptor-positive v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog wild type metastatic colorectal cancer. This combination therapy showed an overall response rate of 50% with an acceptable toxicity profile, which suggests further studies are warranted. Background: Despite the comparable clinical benefit of XELOX (capecitabine with oxaliplatin) and FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), the value of XELOX treatment in combination with cetuximab for metastatic colorectal cancer (mCRC) remains largely unknown. Patients and Methods: In this clinical trial we evaluated the efficacy and safety of weekly/biweekly cetuximab administration combined with biweekly XELOX in patients with previously untreated v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wild type mCRC. The primary end point was response rate (RR) with confirmation, and the secondary end points included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), dose intensity, and the safety of the protocol treatment. Results: Forty patients who fulfilled the inclusion criteria participated in this study. The median treatment cycle number was 8 and the median dose intensities were 218 mg/m(2)/wk for cetuximab, 34 mg/m(2)/wk for oxaliplatin, and 821 mg/m(2)/d for capecitabine. One patient showed complete response and partial response was observed in 19 patients, giving an overall RR of 50% (95% confidence interval [CI], 33.8%-66.2%). Stable disease was obtained in 13 patients, resulting in a DCR of 82.5% (95% CI, 67.2%-92.7%). The PFS was 6.5 months (95% CI, 3.5-9.6 months), and the OS was 24.3 months (95% CI, 14.9-33.7 months). The safety profile revealed the common Grade 3/4 adverse events to be acneiform eruption (12.5%), peripheral neuropathy (7.5%), and elevated alanine transaminase levels (7.5%). Grade 3/4 thrombocytopenia and neutropenia occurred only in 5.0% and 2.5% of the patients, respectively. Grade 1 hand-foot syndrome (HFS) was not uncommon (20%), whereas Grade 2/3 HFS occurred in only 3 patients (7.5%). No deaths were reported within 30 days of the last dose. Conclusion: Cetuximab with XELOX showed a confirmed overall RR of 50%, which was within the previously reported range of RR. The safety profile showed an acceptable rate and severity of adverse events. In light of the several advantages of XELOX, including convenience and the reported cost-saving aspects, further study of this combination therapy is warranted.
引用
收藏
页码:329 / 336
页数:8
相关论文
共 37 条
[1]   Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience [J].
Adams, R. A. ;
Meade, A. M. ;
Madi, A. ;
Fisher, D. ;
Kay, E. ;
Kenny, S. ;
Kaplan, R. S. ;
Maughan, T. S. .
BRITISH JOURNAL OF CANCER, 2009, 100 (02) :251-258
[2]   Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials [J].
Arkenau, Hendrik-Tobias ;
Arnold, Dirk ;
Cassidy, Jim ;
Diaz-Rubio, Eduardo ;
Douillard, Jean-Yves ;
Hochster, Howard ;
Martoni, Andrea ;
Grothey, Axel ;
Hinke, Axel ;
Schmiegel, Wolff ;
Schmoll, Hans-Joachim ;
Porschen, Rainer .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) :5910-5917
[3]  
BOKEMEYER C, 2007, J CLIN ONCOL, V25
[4]   Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK [J].
Borner, M. ;
Koeberle, D. ;
Von Moos, R. ;
Saletti, P. ;
Rauch, D. ;
Hess, V. ;
Trojan, A. ;
Helbling, D. ;
Pestalozzi, B. ;
Caspar, C. ;
Ruhstaller, T. ;
Roth, A. ;
Kappeler, A. ;
Dietrich, D. ;
Lanz, D. ;
Mingrone, W. .
ANNALS OF ONCOLOGY, 2008, 19 (07) :1288-1292
[5]   Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis [J].
Bouchahda, M. ;
Macarulla, T. ;
Liedo, G. ;
Levi, F. ;
Elez, M. E. ;
Paule, B. ;
Karaboue, A. ;
Artru, P. ;
Tabernero, J. ;
Machover, D. ;
Innominato, P. ;
Goldschmidt, E. ;
Bonnet, D. ;
Ducreux, M. ;
Castagne, V. ;
Guimbaud, R. .
MEDICAL ONCOLOGY, 2011, 28 :S253-S258
[6]   XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results [J].
Cassidy, J. ;
Clarke, S. ;
Diaz-Rubio, E. ;
Scheithauer, W. ;
Figer, A. ;
Wong, R. ;
Koski, S. ;
Rittweger, K. ;
Gilberg, F. ;
Saltz, L. .
BRITISH JOURNAL OF CANCER, 2011, 105 (01) :58-64
[7]   Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature [J].
Chan, David L. ;
Pavlakis, Nick ;
Shapiro, Jeremy ;
Price, Timothy J. ;
Karapetis, Christos S. ;
Tebbutt, Niall C. ;
Segelov, Eva .
PLOS ONE, 2015, 10 (08)
[8]  
Chang David Z, 2005, Clin Adv Hematol Oncol, V3, P400
[9]   Cetuximab plus FOLFOX-4 in Untreated Patients with Advanced Colorectal Cancer: A Gruppo Oncologico dell'Italia Meridionale Multicenter Phase II Study [J].
Colucci, Giuseppe ;
Giuliani, Francesco ;
Garufi, Carlo ;
Mattioli, Rodolfo ;
Manzione, Luigi ;
Russo, Antonio ;
Lopez, Massimo ;
Parrella, Paola ;
Tommasi, Stefania ;
Copetti, Massimiliano ;
Daniele, Bruno ;
Pisconti, Salvatore ;
Tuveri, Guido ;
Silvestris, Nicola ;
Maiello, Evaristo .
ONCOLOGY, 2010, 79 (5-6) :415-422
[10]   Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer [J].
Conroy, T. ;
Hebbar, M. ;
Bennouna, J. ;
Ducreux, M. ;
Ychou, M. ;
Lledo, G. ;
Adenis, A. ;
Faroux, R. ;
Rebischung, C. ;
Kockler, L. ;
Douillard, J. Y. .
BRITISH JOURNAL OF CANCER, 2010, 102 (01) :59-67